Desvenlafaxine (O-desmethylvenlafaxine), paliperidone (9-hydroxyrisperidone), and febuxostat were ranked as predicted TRPA1 inhibitors with potential use in MS management. This evidence concerns the gene TRPA1 and myeloid sarcoma.